Difference between revisions of "Letrozole (Femara)"
m |
m |
||
| Line 16: | Line 16: | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]][[Category:Endocrine therapy]][[Category:Steroid synthesis inhibitors]] | ||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
| + | [[Category:Breast cancer medications]] | ||
| − | [[Category: | + | [[Category:Drugs FDA approved in 1997]] |
Revision as of 21:15, 5 November 2014
General information
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. Letrozole competitively binds to and inhibits the aromatase by binding to the heme of the enzyme's cytochrome P450.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Letrozole (Femara) patient drug information (Chemocare)[4]
- Letrozole (Femara) patient drug information (UpToDate)[5]